Business Context and Reporting Period
This Form 6-K filing summarizes the unaudited financial results for GSK plc and its consolidated subsidiaries for the second quarter of 2026 (ended June 30, 2026) and the year-to-date period. The report reflects the company's performance as a global biopharma leader, highlighting a strategic pivot toward late-stage R&D acceleration and cost restructuring.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Turnover | £8,409m (+5% AER) | £7,986m | £16,038m (+3% AER) | £15,502m |
| Total Operating Profit | £481m (-76% AER) | £2,023m | £2,774m (-35% AER) | £4,239m |
| Core Operating Profit | £2,800m (+6% AER) | £2,631m | £5,450m (+6% AER) | £5,164m |
| Profit Attributable to Shareholders | £435m | £1,443m | £2,172m | £3,067m |
| Total EPS | 10.8p (-69%) | 35.5p | 54.1p (-28%) | 75.3p |
| Core EPS | 50.5p | 46.5p | 97.1p | 91.4p |
| Free Cash Flow | £1,994m | £1,126m | £2,809m | £1,823m |
| Total Net Debt | £15,132m | £13,735m | £15,132m | £13,735m |
Material Changes vs. Prior Period
- Revenue Growth: Total turnover grew 5% at actual exchange rates (AER) in Q2, driven by strong performance in Specialty Medicines (+14%) and Vaccines (+9%). General Medicines declined 9% due to Trelegy volume impacts and competitive pressures.
- Profitability Decline (Total): Total operating profit fell 76% year-over-year, primarily due to significant non-cash impairments (£1,895m) related to the discontinuation of camlipixant and the Alector collaboration, alongside higher R&D investment.
- Core Performance: Excluding adjusting items, Core operating profit grew 6% in Q2, reflecting underlying business strength and favorable product mix.
- Debt Position: Net debt increased by £679m to £15.1 billion, driven by acquisition costs (RAPT Therapeutics and 35Pharma), dividends, and share buybacks, partially offset by strong free cash flow.
Guidance, Outlook, and Management Commentary
Accelerate Growth Programme
GSK launched a 3-year "Accelerate Growth" programme targeting £1.9 billion in annual savings by 2029 (total costs of £2.4 billion). The initiative aims to simplify the organization, reallocate capital to the late-stage pipeline, and improve operating margins.
Pipeline and R&D
- Accelerations: Identified 7 asset accelerations across 18 indications in Oncology, Respiratory, Hepatology, and Vaccines.
- Trials: Expectation increased to 20+ Phase III trial starts in 2026 (previously 10).
- Key Milestones: FDA approval for Jideytro (lung cancer); positive Phase III data for Ris-Rez (lung cancer); pivotal data for bepirovirsen (hepatitis B functional cure); and expanded approval for Arexvy in Japan.
US Government Agreement
GSK finalized an agreement with the US Government to lower prescription medicine costs, securing relief from Section 232 tariffs through January 2029 and committing to the voluntary Generous Model.
Dividends and Buybacks
- Declared a Q2 2026 dividend of 17p per share.
- Completed a £2 billion share buyback programme in June 2026.
Investor Verification Checklist
- Impairment Impact: Verify the long-term impact of the £1.895 billion impairment charge on future R&D spend and profitability.
- Restructuring Execution: Monitor the realization of the £1.9 billion annual savings target under the "Accelerate Growth" programme.
- Pipeline Success Rates: Track the outcomes of the accelerated Phase III trials, particularly for Ris-Rez, Mo-Rez, and bepirovirsen.
- US Pricing Environment: Assess the financial impact of the US Government agreement and the Generous Model on future US revenue margins.
- Debt Servicing: Review the sustainability of the increased net debt level (£15.1bn) against projected free cash flow generation.